Journal of Clinical Immunology

, Volume 25, Issue 3, pp 202–208 | Cite as

Evaluation of a New Fluorescent-Enzyme Immuno-Assay for Diagnosis and Follow-up of ANCA-Associated Vasculitis

  • J. G. M. C. Damoiseaux
  • M. C. Slot
  • M. Vaessen
  • C. A. Stegeman
  • P. Van Paassen
  • J. W. Cohen Tervaert
Article

Abstract

In this study we have evaluated a new, fully automated fluorescent-enzyme immuno-assay (FEIA) for detection and quantification of anti-PR3 and anti-MPO ANCA in diagnosis and follow-up of ANCA-associated small vessel vasculitis (AAV). PR3- and MPO-ANCA were determined by FEIA technology in (1) sera of 87 consecutive patients with biopsy-proven, pauci-immune necrotizing crescentic glomerulonephritis (NCGN) and 72 controls; (2) 120 sera (60 patients with Wegener’s granulomatosis and 60 controls) that were previously used in a multicentre comparison of direct and capture ELISAs for PR3-ANCA; (3) in samples preceding relapse in 23 PR3-AAV patients with and 23 matched PR3-AAV patients without relapse for prediction of relapses. PR3- and/or MPO-ANCA detection in pauci-immune NCGN by FEIA revealed an overall sensitivity of 82.8%. The FEIA specificity was 96% and 100% for PR3- and MPO-ANCA, respectively. The overall sensitivity of MPO- and PR3-ANCA could be increased to 88.5% by lowering the cut-off values without affecting the specificity (ROC-curve analysis), which is similar to a multistep ANCA procedure that combines indirect immunofluorescence with direct and capture ELISAs. The sensitivity for Wegener’s granulomatosis (WG) of the PR3-ANCA FEIA (60%) was more comparable to direct ELISAs (64%) than to capture ELISAs (74%). A rise of 100% in ANCA level as measured by FEIA appeared optimal (ROC-curve) for prediction of relapses and such a rise was observed in 26 patients. In 18 of these 26 patients the rise was followed by a relapse (PPV 69%), whereas in 15 of the 20 patients without a rise no relapse was observed (NPV 75%). In conclusion, detection of PR3- and MPO-ANCA by FEIA has excellent performance in terms of diagnosis of AAV patients. Furthermore, detection of rises in PR3-ANCA by FEIA for prediction of relapses gives results comparable to other techniques.

Key Words

ANCA fluorescent-enzyme immuno-assay myeloperoxidase proteinase 3 vasculitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 337:1512–1523, 1997CrossRefPubMedGoogle Scholar
  2. 2.
    Savige J, Davies D, Falk RJ, Jennette JC, Wiik A: Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features. Kidney Int 57:846–862, 2000CrossRefPubMedGoogle Scholar
  3. 3.
    Rutgers A, Heeringa P, Damoiseaux JG, Cohen Tervaert JW: ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. Eur J Intern Med 14:287–295, 2003.CrossRefPubMedGoogle Scholar
  4. 4.
    Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL: Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126:866–873, 1997PubMedGoogle Scholar
  5. 5.
    Kallenberg CG, Mulder AH, Cohen Tervaert JW: Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. Am J Med 93:675–682, 1992CrossRefPubMedGoogle Scholar
  6. 6.
    Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, Pollock W, Pusey C, Savage CO, Silvestrini R, van der Woude F, Wieslander J, Wiik A: International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111:507–513, 1999PubMedGoogle Scholar
  7. 7.
    Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R, Pusey C, Pollock W, Trevisin M, Wiik A, Wong R: Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120:312–318, 2003CrossRefPubMedGoogle Scholar
  8. 8.
    Stegeman CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 17:2077–2080, 2002CrossRefPubMedGoogle Scholar
  9. 9.
    Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12–17, 1994.PubMedGoogle Scholar
  10. 10.
    Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, Limburg PC, Cohen Tervaert JW: Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum 43:2025–2033, 2000CrossRefPubMedGoogle Scholar
  11. 11.
    Slot MC, Cohen Tervaert JW, Boomsma MM, Stegeman CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 51:269–273, 2004CrossRefPubMedGoogle Scholar
  12. 12.
    Csernok E, Holle J, Hellmich B, Willem J, Tervaert C, Kallenberg CG, Limburg PC, Niles J, Pan G, Specks U, Westman K, Wieslander J, De Groot K, Gross WL: Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener’s granulomatosis: First results from a multicentre study. Rheumatology (Oxford) 43:174–180, 2004Google Scholar
  13. 13.
    Tiebosch AT, Wolters J, Frederik PF, van der Wiel TW, Zeppenfeldt E, van Breda Vriesman PJ: Epidemiology of idiopathic glomerular disease: A prospective study. Kidney Int 32:112–116, 1987PubMedGoogle Scholar
  14. 14.
    Boomsma MM, Damoiseaux JG, Stegeman CA, Kallenberg CG, Patnaik M, Peter JB, Cohen Tervaert JW: Image analysis: A novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener’s granulomatosis. J Immunol Methods 274:27–35, 2003CrossRefPubMedGoogle Scholar
  15. 15.
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192, 1994PubMedGoogle Scholar
  16. 16.
    Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, The TH, von dem Borne AE, Kallenberg CG: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 37:799–806, 1990PubMedGoogle Scholar
  17. 17.
    Boomsma MM, Stegeman CA, Oost-Kort WW, Kallenberg CG, Moguilevsky N, Limburg PC, Cohen Tervaert JW: Native and recombinant proteins to analyze auto-antibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. J Immunol Methods 254:47–58, 2001CrossRefPubMedGoogle Scholar
  18. 18.
    Rutgers A, Damoiseaux J, Roozendaal C, Limburg PC, Stegeman CA, Cohen Tervaert JW: ANCA-GBM dot-blot: Evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis. J Clin Immunol 24:435–440, 2004CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • J. G. M. C. Damoiseaux
    • 1
    • 3
  • M. C. Slot
    • 1
  • M. Vaessen
    • 1
  • C. A. Stegeman
    • 2
  • P. Van Paassen
    • 1
  • J. W. Cohen Tervaert
    • 1
  1. 1.Department of Clinical and Experimental ImmunologyUniversity Hospital MaastrichtThe Netherlands
  2. 2.Department of NephrologyUniversity Hospital GroningenThe Netherlands
  3. 3.Department of Clinical and Experimental ImmunologyUniversity Hospital MaastrichtAZ MaastrichtThe Netherlands

Personalised recommendations